| publication name | Interleukin -37 as an anti-1 inflammatory cytokine: Does its relation to disease activity suggest its 2 potential role in rheumatoid arthritis therapy? |
|---|---|
| Authors | Eman Baraka1, Mona Balata2,3, Shereen Ahmed4,Afaf Khamis5 and Enas Elattar2 |
| year | 2021 |
| keywords | |
| journal | Egyptian Rheumatology and Rehabilitation |
| volume | Not Available |
| issue | Not Available |
| pages | Not Available |
| publisher | Not Available |
| Local/International | Local |
| Paper Link | Not Available |
| Full paper | download |
| Supplementary materials | Not Available |
Abstract
Background: This study aimed to measure the serum and synovial interleukin (IL) -37 levels in 5 rheumatoid arthritis (RA) patients compared to patients with primary knee osteoarthritis (PKOA) and 6 healthy controls and to detect its relation to RA disease activity. Results: This cross-sectional study 7 included 50 RA patients with a mean age of 40.24±8.62 years, 50 patients with PKOA with a mean age 8 of 56.69±4.21, and 40 healthy controls with a mean age of 41.75 ±7.38 years. The mean serum IL-37 9 level in the RA patients (382.6±73.97 pg/ml) was statistically significantly (p 0.94). Both serum and 12 synovial IL-37 levels were significantly positively correlated with disease activity scores (r= 0.92, P< 13 0.001 and r= 0.85, P< 0.001), tender joint counts (r= 0.83, P< 0.001 and r= 0.82, P< 0.001 ), swollen 14 joint counts (r= 0.72, P< 0.001 and r= 0.60, P< 0.001), visual analogue scores (r=0.82, P< 0.001 and r= 15 0.82, P< 0.001), erythrocyte sedimentation rate (r= 0.75, P